不同照射剂量及照后培养不同时间小鼠骨髓基质细胞损伤的变化

目的 :研究γ射线照射剂量及照射后培养时间对体外培养的骨髓基质细胞 (BMSC)损伤的影响。方法 :体外培养的BMSC随机分为正常组和不同剂量照射组 ,利用流式细胞仪 (FCM)、HE染色等技术观察处理后BMSC凋亡率和坏死率的变化。结果 :照射剂量从 0增至 5 0Gy时 ,凋亡率和坏死率随照后培养时间的延长其增加的幅度较小 ,当照射剂量从 5 0Gy增至 70Gy时 ,其增加幅度较大 ;当剂量大于 70Gy时 ,BMSC的损伤主要表现为坏死率的相对增高。结论 :BMSC的凋亡和坏死与照射剂量和照后培养时间有关 ,且表现出一定的规律性     

生长激素对糖尿病及其微血管病变的影响

目的 :探讨生长激素对糖尿病及其微血管病变的影响。方法 :采用放射免疫法测定 6 7例Ⅱ型糖尿病患者及 18例正常人的血清生长激素 (GH)及胰岛素 (INS)水平。结果 :糖尿病合并微血管病变组 ,空腹生长激素 (FGH)明显高于正常对照组 (P <0 .0 1)及糖尿病无微血管病变组 (P <0 .0 1)。糖尿病无微血管病变组的FGH与正常对照组的FGH相比未见明显差异 (P >0 .0 5 )。餐后 2h的生长激素 (PGH)在 3组之间均无显著差异 (P >0 .0 5 )。FGH与HbA1c、空腹血糖 (FBS)呈正相关 (r=0 .5 46 ,P <0 .0 1;r=0 .437,P <0 .0 1) ,与UAER呈正相关 (r=0 .486 ,P <0 .0 1) ;FGH与病程无相关 (r=0 .2 2 ,P >0 .0 5 ) ,与FINS无相关 (r =- 0 .0 2 9,P >0 .0 5 )。结论 :GH水平的增高 ,与糖代谢紊乱有关 ,参与了糖尿病微血管病变的发生。     

The effect of electro-acupuncture on motor function recovery in patients with acute cerebral infarction: a randomly controlled trial.

The aim of this study is to investigate the effect of electro-acupuncture treatment in acute phase of cerebral infarction on the motor functions. In this randomly controlled trial, 86 patients were allocated to two groups, the experimental group given clinical and electro-acupuncture treatments for a period of 4 weeks, and the control group given clinical treatment plus active and/or passive functional exercise. The result showed that the level of impairment and disability in both groups were improvement according to the Chinese Stroke Scale, Brunnstrom-Fugl-Meyer score, and Barthel Index throughout the study and 3 months after. The motor functions and the activities of daily living (ADL) were improved significantly in the electro-acupuncture group as compared with the control group (P < 0.05). Also, the results showed greater reduction of neurological deficit in the electro-acupuncture group than in the control group. CONCLUSION: Early acupuncture treatment for acute stroke patients may improve motor functions, and consequently the activities of daily living.     

铁死亡相关肌肉骨骼系统疾病的概述及中医药干预进展

铁死亡是一种新型的细胞死亡形式,与铁过载和脂质过氧化有关,在许多疾病的发展中具有重要作用。骨质疏松症、骨关节炎、类风湿关节炎、骨肉瘤、脊髓损伤、肌少症等肌肉骨骼系统疾病严重影响患者生活质量,已成为全球公共卫生系统的主要负担。铁死亡与上述肌肉骨骼系统疾病的发生发展密切相关,表明铁死亡可能成为肌肉骨骼系统疾病的治疗的新靶点。中医药在肌肉骨骼系统疾病治疗中有其独特的优势,已有大量研究证实中医药通过铁死亡途径参与肌肉骨骼系统疾病的调节,显示出良好的研究前景。通过探讨铁死亡与肌肉骨骼系统疾病的关联,总结中医药通过介导铁死亡防治肌肉骨骼系统疾病研究进展,为开发新的治疗策略及中医药更好的治疗肌肉骨骼系统疾病治疗提供思路。     

河北省燕山及太行山山脉黄芩生态适宜性区划研究

目的:研究黄芩在河北省燕山及太行山山脉生态适宜性区划。方法:通过第四次全国中药资源普查等方式获取黄芩分布位点信息,利用地理信息系统技术和最大信息熵模型分析其分布区的主导生态因子、数值和权重,得出黄芩药材在河北省的生态适宜生长区。结果:研究表明,海拔、坡度、最暖季降水量、最湿月降水量、年均温、土壤类型、植被类型7项环境因子是影响黄芩分布的主要生态因子;黄芩在河北省的生态适宜生长区主要分布在承德、张家口、保定等地的燕山及太行山山脉区域。结论:可在太行山山脉的承德市、张家口市、保定市,燕山山脉的秦皇岛市引种栽培黄芩。     

A Descriptive Analysis of the Epidemiology and Motivations for Laser Tattoo Removal in an Underserved Population

Journal of Community Health - Tattoos of formerly gang-involved and incarcerated individuals can negatively impact their ability to reintegrate into society. Laser tattoo removal is essential to...     

Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma

BackgroundRadical/cytoreductive nephrectomy or nephron-sparing surgery may be thought to be not safe or unfeasible in some renal cell carcinoma (RCC) patients in which tumor is locally advanced or highly complicated. Neoadjuvant therapy may reduce the volume of the tumor, thus facilitates surgery. The aim the study is to evaluate the efficacy and safety of neoadjuvant combination of pazopanib or axitinib and PD-1-activated dendritic cell-cytokine-induced killer (PD-1/DC-CIK) cell immunotherapy in those patients.MethodsData from 16 RCC patients who received neoadjuvant pazopanib (Group P, n=9) or axitinib (Group A, n=7) plus PD-1/DC-CIK cells immunotherapy were reviewed retrospectively. A total of 9 participants that were potential candidates for radical/cytoreductive nephrectomy (RN/CN) had locally advanced tumor and 5 participants with partial nephrectomy (PN) absolute indications had highly complicated tumors. The efficacy outcomes were based on volume changes of the primary tumor, lymph nodes, and tumor thrombus in 13 participants with complete computed tomography (CT) imaging. The treatment-related toxicities and surgical complications were also reported.ResultsWith a median of 2.1 months treatment, the overall volume of the tumors decreased by a median of 42.30% [interquartile range (IQR): 19.37–66.78%]. Specifically, the median reduction of tumor volume was 88.77 and 15.50 cm³ in group P and group A, respectively (P=0.014). However, participants in Group P were more likely to experience grade 3 or 4 treatment-related adverse events (AEs) than those in Group A (44.4% vs. 0). Finally, all participants were candidates for appropriate surgery after neoadjuvant therapy (as assessed by the surgeon), and 10 participants accepted surgery, including 5 PN, 4 RN/CN, and 1 lymph node dissection. A solitary participant had Clavien grade IV acute renal failure required dialysis and another had grade II lymphatic leakage.ConclusionsNeoadjuvant combination of pazopanib or axitinib and PD-1/DC-CIK cells immunotherapy was well-tolerated and could effectively reduce the volume of tumors in locally advanced or highly complicated RCC patients.     

含不同启动子的腺病毒载体介导的人β2肾上腺素能受体基因在心肌细胞的表达

目的观察不同的启动子cmv、mlc-2v对腺病毒载体介导的人β